Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients

• Published in: Clinical pharmacology and therapeutics Vol. 87; no. 1; p. 57
• Main Authors: Pautas, E, Moreau, C, Gouin-Thibault, I, Golmard, J-L, Mahé, I, Legendre, C, Taillandier-Hériche, E, Durand-Gasselin, B, Houllier, A-M, Verrier, P, Beaune, P, Loriot, M-A, Siguret, V
• Format: Journal Article
• Language: English
• Published: United States 01.01.2010
• Subjects: Age Factors; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases - genetics; Cohort Studies; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System - genetics; Cytochrome P450 Family 4; Dose-Response Relationship, Drug; Epoxide Hydrolases - genetics; Female; Frail Elderly; Genetic Testing; Genetic Variation - drug effects; Genetic Variation - genetics; Hospitalization - trends; Humans; International Normalized Ratio - trends; Male; Mixed Function Oxygenases - genetics; Polymorphism, Genetic - genetics; Prospective Studies; Risk Factors; Vitamin K Epoxide Reductases; Warfarin - pharmacology

Determining the optimal dose of warfarin for frail elderly patients is a challenging task because of the low dose requirements in such patients, the wide interindividual variability of response, and the associated risk of bleeding. The objective of this study was to address the influence of 13 commo...